Melanoma

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on February 25

RAMAT GAN, Israel, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing…

3 months ago
Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial OfficerIovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

Iovance Biotherapeutics Appoints Dan Kirby as Chief Commercial Officer

SAN CARLOS, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on…

3 months ago
Rakuten Medical Completes Technology Transfer of IR700 Manufacturing and Establishes Exclusive Position in its SupplyRakuten Medical Completes Technology Transfer of IR700 Manufacturing and Establishes Exclusive Position in its Supply

Rakuten Medical Completes Technology Transfer of IR700 Manufacturing and Establishes Exclusive Position in its Supply

IR700, a light-activatable dye, is a key component of the Alluminox™ platform-based photoimmunotherapyIR700 is being investigated in several other therapeutic…

3 months ago
PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AIPathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI

PathAssist Derm Launches on AISight®: Advancing Dermatopathology Research Workflows using AI

Now available on the AISight® Platform, PathAssist Derm is an AI-assisted histopathology tool that enhances dermatopathology research workflows, accelerating skin…

3 months ago
IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine CandidateIO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

IO Biotech Announces Publication of Preclinical Data Investigating Immune-Modulatory Effects of IO112, an Arginase 1-Targeting Therapeutic Cancer Vaccine Candidate

– Submission of Investigational New Drug Application (IND) to US FDA expected in 2025 – NEW YORK, Feb. 04, 2025 (GLOBE NEWSWIRE)…

3 months ago
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity…

3 months ago
BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

BriaCell Announces Resolution of Lung Metastasis in First Patient treated with Bria-OTS™

Lung metastasis (from metastatic breast cancer) resolved - after only 2 months (4 doses) of treatment with Bria-OTS™ monotherapyNo toxicity…

3 months ago
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow SeriesPhio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Registration Link for Presentation and live Q&A to take place, Tuesday February 4, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp.…

3 months ago
Potential Revolution in Healthcare Brewing, Powered by AI InnovationPotential Revolution in Healthcare Brewing, Powered by AI Innovation

Potential Revolution in Healthcare Brewing, Powered by AI Innovation

USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Jan. 29, 2025 /PRNewswire/ -- USA News…

3 months ago
KUBTEC Awarded Tumor Localization Equipment and Related Accessories Category Agreement with Premier, Inc.KUBTEC Awarded Tumor Localization Equipment and Related Accessories Category Agreement with Premier, Inc.

KUBTEC Awarded Tumor Localization Equipment and Related Accessories Category Agreement with Premier, Inc.

CONTACT:Richard WheltonHead / Director of Marketing, KUBTECrwhelton@kubtec.com(203) 364-8544 ext. 127 STRATFORD, Conn., Jan. 22, 2025 /PRNewswire/ -- KUBTEC has been awarded…

3 months ago